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Misfolding of proteins containing abnormal expansions of polyglutamine (polyQ) repeats is associated with cytotoxicity in sev-
eral neurodegenerative disorders, including Huntington’s disease. Recently, the eukaryotic chaperonin TRiC hetero-oligomeric
complex has been shown to play an important role in protecting cells against the accumulation of misfolded polyQ protein ag-
gregates. It is essential to elucidate how TRiC function is regulated to better understand the pathological mechanism of polyQ
aggregation. Here, we propose that vaccinia-related kinase 2 (VRK2) is a critical enzyme that negatively regulates TRiC. In mam-
malian cells, overexpression of wild-type VRK2 decreased endogenous TRiC protein levels by promoting TRiC ubiquitination,
but a VRK2 kinase-deadmutant did not. Interestingly, VRK2-mediated downregulation of TRiC increased aggregate formation
of a polyQ-expanded huntingtin fragment. This effect was ameliorated by rescue of TRiC protein levels. Notably, small interfer-
ence RNA-mediated knockdown of VRK2 enhanced TRiC protein stability and decreased polyQ aggregation. The VRK2-medi-
ated reduction of TRiC protein levels was subsequent to the recruitment of COP1 E3 ligase. Among the members of the COP1 E3
ligase complex, VRK2 interacted with RBX1 and increased E3 ligase activity on TRiC in vitro. Taken together, these results dem-
onstrate that VRK2 is crucial to regulate the ubiquitination-proteosomal degradation of TRiC, which controls folding of poly-
glutamine proteins involved in Huntington’s disease.
Mutant proteins containing abnormal polyglutamine (polyQ)expansions beyond a critical threshold are involved in sev-
eral late-onset neurodegenerative disorders (1). For example, the
mutation responsible for Huntington’s disease (HD) is 40
polyQ expansions in the N terminus of huntingtin (Htt), a ubiq-
uitously expressed cytoplasmic protein. HD is characterized by
the selective and progressive dysfunction and death of neurons,
mainly in the striatum, which manifest as voluntary movement
dysfunction, personality changes, and dementia (2, 3). The caus-
ative mutant Htt protein is prone to proteolysis, and the resulting
N-terminal fragments containing expanded polyQ repeats transi-
tion into a toxic conformation (4, 5). This eventually leads to the
accumulation of intracellular aggregates or inclusion bodies, often
consisting of insoluble, heat-stable -sheet amyloid deposits (6).
The length of polyQ tracts and the age-dependent accumulation
of the mutant Htt contribute to HD onset and progression (7).
Aggregation-based diseases disproportionately affect postmitotic
cells, such as neurons, presumably because they cannot dilute the
toxic protein aggregates during cell division (6).
Molecular chaperones are the first line of defense against
misfolded, aggregation-prone proteins and are the most potent
suppressors of neurodegeneration (8). Heat shock protein 70
(HSP70) and HSP40 have been shown to protect cells against
polyQ aggregation and toxicity in various cellular and animal
models (9–12). In addition, the eukaryotic chaperonin TCP-1
ring complex (TRiC) (also known as CCT [chaperonin-con-
taining TCP-1]), a member of the HSP60 family, was also iden-
tified to have a significant role in protecting against polyQ
aggregation in Caenorhabditis elegans (13). TRiC consists of eight
homologous subunits arranged in two octameric rings stacked
back to back that form a central cavity in which substrate proteins
are captured and properly folded in an ATP-dependent manner
(14, 15). Potential TRiC substrates include skeletal proteins, Von
Hippel-Lindau tumor suppressor protein (VHL), and many
WD40 repeat proteins (16). Recently, several studies provided ev-
idence that TRiC inhibits polyQ aggregation and cytotoxicity dur-
ing the early stages of the aggregation process (17–19). It is there-
fore necessary to reveal the mode of TRiC regulation to better
understand the upstream pathway of TRiC-assisted polyQ protein
folding.
Vaccinia-related kinase 2 (VRK2) is a novel serine/threo-
nine kinase similar in sequence and structure to the catalytic
domain of the casein kinase 1 (CK1) family (20). There are two
isoforms of human VRK2; VRK2A is primarily in the endoplas-
mic reticulum (ER) and mitochondria because of its C-termi-
nal transmembrane (TM) domain, and VRK2B, which lacks
this domain, is found in both the cytosol and the nucleus (21).
Functionally, VRK2 suppresses the hypoxia-induced TAK1–
JIP1–Jun N-terminal protein kinase cascade by interacting
with TAK1, which results in the downregulation of AP-1-de-
pendent transcription (22). VRK2 also inhibits MEK/extracel-
lular signal-regulated kinase signal transduction by interacting
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with the KSR1 scaffold protein in breast cancer cell lines, which
leads to a signaling imbalance (23). In addition, VRK2 en-
hances cell survival through interacting with BHRF1, an anti-
apoptotic Epstein-Barr virus protein (24), and Bcl-xL, an anti-
apoptotic BH (Bcl-2 homology) domain protein (25). Because
VRK2 has a sequence similar to that of the catalytic domain of
vaccinia-related kinase 1 (VRK1), VRK2 also phosphorylates
histone H3 (26), p53 (21), and barrier to autointegration factor
(BAF) (27), which supposedly compensates for the VRK1 func-
tion. Recently, VRK2 was reported to phosphorylate NFAT1,
which affects cell invasion through enhanced Cox2 expression
(28). However, other VRK2 functions remain largely unex-
plored because VRK2 substrates have rarely been identified.
In the study described in this report, we addressed whether and
how VRK2 regulates polyQ aggregation. The eukaryotic chaper-
onin TRiC was degraded by the ubiquitin-proteasome system
(29), but its molecular mechanism has remained largely unex-
plored. We describe the molecular mechanism of TRiC protein
ubiquitination through recruitment of the mammalian constitu-
tive photomorphogenic 1 (COP1) E3 ligase complex. These find-
ings suggest that VRK2 plays a critical role in regulating the func-
tion of the chaperonin TRiC, which is involved in polyQ protein
aggregation.
MATERIALS AND METHODS
Plasmids. VRK2 (VRK2A; accession number NM_027260) and TRiC ex-
pression constructs were generated by amplifying mouse full-length
VRK2 and TRiC subunits (CCT1 to CCT8) by PCR from a day 16 mouse
embryo cDNA library (Clontech, Mountain View, CA). For mammalian
expression constructs, VRK2 and its kinase-dead (KD) mutant (VRK2-
KD), generated by site-directed mutagenesis (Lys61 to Ala), were sub-
cloned into the pFlag-CMV2 (Sigma, St. Louis, MO) and the pDsRed1-N1
and pDsRed1-C1 (BD Biosciences, San Jose, CA) vectors. TRiC subunits
were subcloned into the pEGFP-C1 (BD Biosciences) and pcDNA3 (In-
vitrogen, Carlsbad, CA) vectors modified with a human influenza virus
hemagglutinin (HA) epitope. For domain mapping, VRK2-N (amino ac-
ids 1 to 300), VRK2-C (amino acids 301 to 508), CCT4-N term (amino
acids 1 to 220), CCT4 apical (amino acids 221 to 392), CCT4 api-C
(amino acids 221 to 539), and CCT4-C term (amino acids 393 to 539)
were subcloned into a pGEX-4T-3 vector. For expression in Escherichia
coli, the VRK2 and TRiC subunits were subcloned into the pProEX,
pGEX-4T-1, and pGEX-4T-3 (Amersham, Piscataway, NJ) and pET-
SUMO (Invitrogen) vectors. Htt-exon1-GFP-pcDNA3.1 (where the
length of the polyQ tract was 25 or 103) was a gift from Judith Frydman
(Stanford University, Stanford, CA). pGEX6P1-COP1 (accession number
AF527539) was kindly provided by Vishva M. Dixit (Genentech, Inc.,
South San Francisco, CA). The RING-box 1 (RBX1; accession number
NM_014248) and Cul4A (accession number AY365124) constructs were
gifts from Jong-Bok Yoon (Yonsei University, Seoul, South Korea). The
DDB1 (accession number NM_001923) construct was a gift from Yue
Xiong (Addgene plasmid 19909).
Biochemicalmethods. Extract and protein preparation, immunopre-
cipitation, glutathione S-transferase (GST) pulldown, and Western blot-
ting were performed as previously described (30).
In vitro kinase assay. Kinase assays utilizing 1 g recombinant GST-
VRK2 (or HIS-VRK2) and 1g recombinant proteins (HIS-CCTx [where
x is subunit 1 to 8], GST-COP1, or GST-RBX1) as the substrates were
performed at 30°C in a 20-l reaction mixture containing kinase buffer
(20 mM Tris-HCl [pH 7.5], 5 mM MgCl2, 0.5 mM dithiothreitol, 150 mM
KCl, [-32P]ATP). After 30 min, reactions were resolved by sodium do-
decyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and visu-
alized with autoradiography.
Fluorescence microscopy. Mammalian cells were grown on cover-
slips until they reached 50 to 60% confluence. Transfected cells were
maintained for 24 h, fixed with 4% paraformaldehyde for 15 min, and, if
necessary, immunostained with appropriate primary and fluorescence-
conjugated secondary antibodies. Coverslips were mounted onto a slide
with Fluoromount mounting medium (Sigma). An Axioplan2 fluores-
cence imaging microscope (Carl Zeiss, Jena, Germany) equipped with an
ApoTome device (Carl Zeiss) was used to obtain fluorescence or differen-
tial interference contrast images. We also used superresolution structured
illumination microscopy (SIM; N-SIM; Nikon, Tokyo, Japan). The raw
images were reconstructed to three-dimensional SIM images using NIS-E
software (Nikon). Images were taken with an Eclipse Ti-E research in-
verted microscope with Nikon’s CFI Apo TIRF 100 oil objective lens
(numerical aperture, 1.49) and a 512- by 512-pixel resolution with an
iXon DU-897 electron-multiplying charge-coupled-device camera (An-
dor Technology, Belfast, United Kingdom). Multicolor fluorescent im-
ages were acquired using a diode laser (488 nm, 561 nm). MitoTracker
staining was performed with 250 nM MitoTracker red (CMXRos; Invit-
rogen) for 30 min at 37°C. The cells were fixed with 4% paraformaldehyde
in phosphate-buffered saline (PBS) for 40 min at room temperature.
Mounting was done with Cytoseal XYL mounting medium (UltraCruz
hard-set mounting medium; Santa Cruz).
Yeast two-hybrid assay. A genetic screening using the yeast interac-
tion trap with bait plasmid pEG202 harboring a full-length mouse VRK2
gene and mouse liver cDNA library in the pJG4-5 plasmid was carried out
in Saccharomyces cerevisiae strain EGY48 as previously described (31).
Cell culture and transfection. HEK293T, SK-N-BE(2)C, A549,
U2OS, SH-SY5Y, and HeLa cells were grown in Dulbecco’s modified Ea-
gle medium (DMEM) supplemented with 10% fetal bovine serum (FBS)
and 100 U/ml each of penicillin G and streptomycin. Transient transfec-
tion was carried out with the Metafectene reagent (Biontex, Munich, Ger-
many) or a Microporator system (Invitrogen), as described in the manu-
facturers’ protocols.
siRNA sequence. The small interference RNA (siRNA) duplex pool
targeting human VRK2 (siVRK2) and COP1 (siCOP1) was obtained from
Dharmacon (Lafayette, CO). The siRNA sequence for the nonspecific
control oligonucleotide was CCUACGCCACCAAUUUCGUdTdT.
Antibodies. Commercially available antibodies were as follows: an-
ti-Flag epitope (M2) from Sigma; anti-HA epitope from Roche
(Mannheim, Germany); anti-glyceraldehyde-3-phosphate dehydroge-
nase (anti-GAPDH) from Calbiochem (San Diego, CA); anti-CCT1, anti-
CCT2, anti-CCT4, anti-CCT7, anticalnexin, and anti-COP1 from Abcam
(Cambridge, United Kingdom); anti-VRK2, anti-green fluorescence pro-
tein (anti-GFP), antiubiquitin, anti-HIS epitope, anti-GST, anti-Tom20,
and anti-lamin B from Santa Cruz Biotechnology (Santa Cruz, CA); and
all fluorescence-conjugated secondary antibodies from Invitrogen.
In vitro ubiquitination assay. For the ubiquitination assay, 1g HIS-
CCT4, 5 g Flag-ubiquitin (Sigma), 1 M UbcH5b (Boston Biochem,
Cambridge, MA), 200 nM rabbit E1 (Boston Biochem), 1 g GST-COP1
(E3), 1 g GST-RBX1, 1 g GST-DDB1, 1 g Cul4A, and 1 g SUMO-
VRK2 were preincubated with 20 mM HEPES (pH 7.3) for 30 min at room
temperature and then incubated in a buffer containing 20 mM HEPES
(pH 7.3), 4 mM ATP, 10 mM MgCl2, and 4 mM dithiothreitol. After
incubation for 2 h at 30°C with gentle agitation, the reaction solutions
were boiled in PBS containing 0.5% Triton X-100 (PBST) with 1% SDS
for 5 min and reduced to 0.1% SDS with PBST for immunoprecipitation
with anti-CCT4. Finally, samples were subjected to SDS-PAGE, followed
by immunoblotting with anti-Flag to detect polyubiquitinated CCT4.
Protein and RNA stability assay. For cycloheximide (CHX)-chase
assays, cells were treated with cycloheximide (Calbiochem) (HEK293T
cells, 100g/ml; HeLa cells, 40g/ml) in isopropanol and harvested at the
indicated times for Western blot analysis. For RNA stability, cells were
treated with 10 g/ml actinomycin D (Sigma) at 0 h and harvested at the
indicated times. Total RNA was isolated using the TRI reagent (Molecular
Research Center, Cincinnati, OH) according to the manufacturer’s in-
Kim et al.
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structions. RNA was reverse transcribed using oligo(dT) (Promega, Fitch-
burg, WI) and Moloney murine leukemia virus reverse transcriptase
(Roche, Indianapolis, IN) in the presence of RNase inhibitor (RNasin;
Promega). CCT4 mRNA levels were detected by quantitative real-time
PCR using StepOnePlus real-time PCR systems (Applied Biosystems, Fos-
ter City, CA) with a SYBR green PCR mixture (Roche). We used primer
pairs specific for GAPDH (forward primer, 5=-GCCATCAATGACCCCT
TCATT-3=; reverse primer, 5=-GCTCCTGGAAGATGGTGATGG-3=)
and CCT4 (forward primer, 5=-AAGCCTTGGACCAAAAGGAA-3=; re-
verse primer, 5=-AAGAGGGAGCCAGCAATGAT-3=).
Filter-trap assay. Cells were lysed in PBST, and protein concentra-
tions were measured. Lysates were diluted in 1% SDS in PBS and boiled
for 5 min. Immediately after cooling, the indicated amounts of proteins
were loaded onto nitrocellulose membranes (pore size, 0.2m) settled on
a dot blotter (Bio-Rad, Hercules, CA). After blocking with 5% skim milk
and PBST for 1 h, the membranes were incubated with mouse anti-GFP
and horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibod-
ies. HRP activity was detected by development in SUPEX solution (Neu-
ronex, South Korea).
Statistical analysis. All statistical analyses were performed with one-
way analysis of variance and post hoc Tukey’s multiple-comparison tests
using GraphPad software. Differences were considered significant when P
was0.05.
RESULTS
VRK2 and chaperonin TRiC interaction. To explore the func-
tional roles of VRK2 (which represents VRK2A), we performed
yeast two-hybrid screening and found that VRK2 interacts with
the CCT2 subunit of the mammalian chaperonin TRiC. In or-
der to verify which subunit of TRiC directly binds to VRK2 in
vitro, all TRiC subunits and VRK2 were purified as HIS (HIS-
CCT) and GST (GST-VRK2) fusion protein forms, respec-
tively, and GST pulldown assays were performed. HIS-CCT1
and -4 were shown to interact with GST-VRK2 (Fig. 1A), which
was confirmed using GST-CCT and HIS-VRK2 constructs by
inversely exchanging fusion proteins. GST-CCT1 and -4 also
bound to HIS-VRK2 (Fig. 1B and C). To test whether VRK2
interacts with TRiC in vivo, immunoprecipitation experiments
were carried out in HEK293T cells. When HA-CCT1 or -4 was
coexpressed with Flag-VRK2, it was efficiently coimmunopre-
cipitated by an anti-Flag antibody (Fig. 1D and E). Even though
purified CCT2 did not bind directly to VRK2 (Fig. 1A and B), a
GST pulldown assay using HA tagging of all CCT subunits also
demonstrated that it was efficiently pulled down by GST-VRK2
(see Fig. S1 in the supplemental material) because all eight
TRiC subunits exist assembled to form a complex. These results
provide evidence that VRK2 interacts with assembled TRiC
complex proteins through specific binding between VRK2 and
CCT1 or -4. Notably, interaction between endogenous VRK2
and CCT subunits (1, 2, 4, and 7) was also detected by immu-
noprecipitation with extracts of A549 cells, which are known to
express high levels of VRK2 (Fig. 1F to I). Fluorescent imaging
analysis has previously shown VRK2 in the ER, mitochondria,
and nuclear envelope, likely because of its TM domain (21).
However, our fluorescent imaging analysis with superresolu-
tion SIM (Nikon N-SIM) clearly showed that VRK2 was mainly
present at the ER and the outer nuclear membrane (see Fig. S2A
to C in the supplemental material); VRK2 colocalized with cal-
nexin (ER protein marker) but not MitoTracker (mitochon-
dria marker). We observed the images generated with Tom20
in detail and found that VRK2 slightly overlaps Tom20 at cer-
tain spots. It seems that a subpopulation of VRK2 is localized in
the outer mitochondrial membrane. VRK2 was reported to reg-
ulate apoptosis through interaction with Bcl-xL in the outer
mitochondrial membrane (25). Although VRK2 was observed
in the nuclear membrane, it did not perfectly overlap the lamin
B (an inner nuclear envelope protein marker). Scanning pro-
files of merged images of VRK2 and lamin B suggested that
VRK2 localizes at the outer nuclear membrane (see Fig. S2D in
the supplemental material). Unlike VRK2, GFP-CCT4 was dif-
fuse throughout the cytoplasm, but it was enriched in DsRed-
VRK2-positive areas (Fig. 1J). Taken together, these results
indicate that VRK2 interacts with the eukaryotic chaperonin
TRiC in vitro and in vivo.
Role of VRK2 in CCT4 downregulation. To determine
whether VRK2 is a substrate for TRiC, we performed pulldown
assays to observe the interactions between VRK2 and various
CCT4 fragments. In the substrate discrimination of TRiC, the
apical domain of TRiC is important for binding its substrates (32).
However, VRK2 interacted with the C-terminal equatorial do-
main of TRiC, which is required for ATP binding (see Fig. S3A in
the supplemental material). This suggests that VRK2 could bind
to CCT1 and -4 due to the highly conserved equatorial domains of
all chaperonin subunits (33). VRK2 domain mapping indicated
that the C-terminal domain of VRK2 (with the exception of the
kinase domain) binds to HIS-CCT4 (see Fig. S3B in the supple-
mental material). On the other hand, VRK2 is a serine-threonine
protein kinase known to phosphorylate substrates such as p53
(21), BAF (27), and NFAT1 (28), and the ability of VRK2 to phos-
phorylate TRiC was of great interest. However, none of the puri-
fied HIS-CCTs were phosphorylated by GST-VRK2 (see Fig. S4A
and B in the supplemental material). Although TRiC did not ap-
pear to be a VRK2 substrate, the interaction between VRK2 and
TRiC led us to hypothesize that VRK2 may be an upstream regu-
lator of TRiC. A VRK2 kinase-dead mutant construct (VRK2-KD)
was generated by point mutating Lys61 into Ala, which eliminated
enzymatic activity and effectively prevented autophosphorylation
(Fig. 2A). VRK2 enzymatic activity was not necessary for VRK2
and CCT4 interaction (see Fig. S4C and D in the supplemental
material). Surprisingly, Flag-VRK2 overexpression in mammalian
cells significantly decreased endogenous CCT4, but VRK2-KD did
not (Fig. 2B, top). As previously reported, the ubiquitin-protea-
some system (UPS) plays an important role in determining TRiC’s
half-life (6 to 7 h) (29). Therefore, we examined the possibility that
VRK2 enhances TRiC degradation by promoting TRiC subunit
ubiquitination. We immunoprecipitated the same extracts used in
the assay whose results are shown at the top of Fig. 2B with an
anti-CCT4 antibody and immunoblotted with an antiubiquitin
antibody. As hypothesized, polyubiquitinated CCT4 was obvi-
ously identified in the presence of VRK2 but not in the presence of
VRK2-KD (Fig. 2B, bottom). We also tested whether VRK2 could
downregulate other CCT subunits. Endogenous CCT1 protein
levels were decreased in cells overexpressing VRK2, but endoge-
nous CCT2 and CCT7 were not (Fig. 2C). Downregulation of
CCT subunits might result from a direct interaction with VRK2,
because CCT1 and -4 directly bound to VRK2 (Fig. 1A and B). To
further confirm VRK2-mediated CCT4 ubiquitination, CCT4
turnover rates were measured in the presence of cycloheximide,
an inhibitor of protein biosynthesis, or actinomycin D, an inhib-
itor of transcription. Although CCT4 mRNA stability was not af-
fected by VRK2 (Fig. 2D), CCT4 protein turnover rates were ac-
celerated in Flag-VRK2-overexpressing cells (Fig. 2E and F).
VRK2 Negatively Regulates the Chaperonin TRiC
February 2014 Volume 34 Number 4 mcb.asm.org 645
 o
n
 M
ay 8, 2015 by PO
STECH LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
Collectively, these results suggest that VRK2 decreases CCT4 pro-
tein levels via enzyme activity-dependent ubiquitination.
Physiological role of VRK2 in polyQ aggregation. To further
examine the physiological role of VRK2-mediated CCT4 down-
regulation, we visualized the polyQ-expanded Htt fragment
fused to GFP. Htt with 103 Q residues (HttQ103) fused to GFP
(HttQ103-GFP) has been used to demonstrate that functional
TRiC is involved in molecular mechanisms that contribute to
polyQ pathogenesis. For instance, TRiC impairment increases the
extent of pathogenic HttQ103-GFP aggregate formation (17).
Conversely, overexpression of either a specific TRiC subunit or all
eight TRiC subunits significantly suppresses aggregate formation
and neuronal cell death (18, 19). We coexpressed DsRed1-VRK2
with pathogenic HttQ103-GFP in HEK293T cells and manually
counted the number of double-labeled cells containing large foci
of aggregated HttQ103-GFP. Whereas VRK1 had no effect on
HttQ103-GFP aggregate formation, VRK2 increased the number
of cells containing foci approximately 3-fold over the number for
a control vector (Fig. 3A and B). This result that VRK2 suppresses
the function of TRiC in preventing polyQ aggregation suggests
that VRK2 facilitates CCT4 degradation (Fig. 2B). Consistent with
the notion that VRK2 enzymatic activity is necessary for modulat-
ing TRiC, VRK2-KD did not promote HttQ103-GFP aggregate
formation (Fig. 3C). The pattern of VRK2-induced polyQ aggre-
gation was also observed in neuroblastoma SH-SY5Y cells, sug-
gesting the possibility that the levels of wild-type VRK2 in neuro-
nal cells are critical for the onset and progression of polyQ
diseases. Accordingly, it would be important to determine
whether VRK2 levels are increased in HD patient brain. Consis-
tent with the fluorescence imaging observations, VRK2 overex-
FIG 1 Interaction and colocalization of VRK2 with chaperonin TRiC. (A, B) GST pulldown assay of VRK2 and TRiC subunit proteins purified from E. coli
cultures. (A) GST-VRK2 bound to HIS-CCT1 or -4. (B) HIS-VRK2 bound to GST-CCT1 or -4. (C) We calculated the amounts of bound VRK2 protein with
GST-CCT proteins. (D, E) Immunoprecipitation assay was performed with the lysates of HEK293T cells cotransfected with Flag-VRK2 and HA-CCT1 (D) or
HA-CCT4 (E) vectors. Encoded HA-CCT1 and HA-CCT4 were coimmunoprecipitated with an anti-Flag antibody. (F to I) The interaction between endogenous
VRK2 and CCT subunit (1, 2, 4, and 7) proteins in A549 cells. Endogenous VRK2 was immunoprecipitated with anti-CCT subunit (1, 2, 4, and 7) antibody, and
immunoprecipitated proteins were analyzed by Western blotting. (J) Colocalization of VRK2 and CCT4. HEK293T cells were cotransfected with Flag-VRK2 and
HA-CCT4 and then stained for Flag (red), HA (green), and nuclei (Hoechst; blue). Arrowheads, concentrated colocalization of CCT4 and VRK2. Bar, 20m. IB,
immunoblot; IP, immunoprecipitation; Ab, antibody.
Kim et al.
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pression increased SDS-resistant aggregates detected by filter-trap
assay (Fig. 3D). Conversely, expression of nonpathogenic
HttQ25-GFP remained diffuse regardless of VRK2 because it folds
well, despite TRiC disruption (Fig. 3E; see Fig. S5 in the supple-
mental material) (17). Taken together, these results suggest that
enhanced expression of wild-type VRK2 accelerates multiple pro-
cesses to trigger polyQ aggregation.
Attenuated polyQ aggregation following CCT4 rescue. Be-
cause VRK2 manifests TRiC protein turnover and increases polyQ
aggregation, we tested whether VRK2-mediated reduction of
TRiC protein levels results in a greater number of polyQ aggre-
gates. To clarify the observed association between VRK2 levels and
polyQ aggregation, we carried out a CCT4 rescue experiment
and measured polyQ aggregate levels with fluorescence imaging
and Western blotting. Dense foci of polyQ aggregates were dra-
matically increased in cells overexpressing wild-type VRK2,
whereas cells coexpressing CCT4 showed attenuated polyQ aggre-
gation and a diffuse fluorescent signal similar to those of cells
expressing the control vector (Fig. 4A and B). To gain more insight
into the effects of CCT4 rescue on polyQ aggregation, we per-
formed Western blotting with anti-GFP against HttQ103. Cells
were lysed with radioimmunoprecipitation assay buffer to obtain
soluble and insoluble polyQ aggregates. VRK2 overexpression
markedly increased the levels of insoluble aggregates that were
detected in the stacking gel due to their SDS insolubility and high
molecular weight (Fig. 4C). Surprisingly, CCT4 cooverexpression
effectively reduced the increased levels of insoluble aggregates in-
duced by VRK2 overexpression down to basal aggregate levels, as
observed in cells transfected with HttQ103 alone. In contrast,
VRK2 overexpression and CCT4 rescue had no effect on soluble
HttQ103 levels. Consistent with the results of fluorescence imag-
ing and Western blotting, CCT4 rescue also decreased the level of
SDS-insoluble aggregates detectable by filter-trap assay (Fig. 4D).
These data suggest that VRK2-mediated TRiC protein turnover is
required for the accumulation of polyQ aggregates.
Decreased polyQ aggregation following VRK2 knockdown.
To assess the role of endogenous VRK2 on TRiC-assisted polyQ
protein folding, U2OS cells were transfected with HttQ103-GFP
and small interference RNA (siRNA) against VRK2 (siVRK2) to
confirm that efficient knockdown of negative regulators can
change endogenous CCT4 levels. CCT4 levels were slightly in-
creased, and SDS-resistant polyQ aggregates were also compara-
tively decreased in cells transfected with siRNA for VRK2 (Fig.
5A). The effect of the targeted knockdown of VRK2 on polyQ
aggregation was examined by fluorescence imaging of cells ex-
pressing HttQ103-GFP for 3 days. In the case of control cells
transfected with the siRNA control (siCont), HttQ103-GFP ag-
gregates were shown in 20% of the GFP-positive cells at day 3.
However, siVRK2-mediated knockdown decreased the propor-
tion of cells containing aggregates to less than 5% of the GFP-
positive cells at day 3. From days 1 to 3, the increasing rate of GFP
foci in VRK2-depleted cells was significantly lower than that in
siCont-treated cells (Fig. 5B and C). These results suggest that
knockdown of VRK2 enhances the functional capacity of TRiC
FIG 2 VRK2 activity-dependent polyubiquitination and degradation of TRiC. (A) Construction of VRK2-KD (K61A). Purified GST-VRK2-KD did not
autophosphorylate because it cannot bind ATP. CBB, Coomassie brilliant blue. (B) Polyubiquitination and degradation of CCT4 are dependent on VRK2
enzymatic activity. Lysates of cells overexpressing Flag-VRK2 or VRK2-KD were immunoblotted with anti-CCT4 antibody. TRiC levels decreased following
Flag-VRK2 overexpression (top). The same lysates were immunoprecipitated with an anti-CCT4 antibody and immunoblotted with an antiubiquitin antibody.
CCT4 polyubiquitination was promoted by Flag-VRK2 but not Flag-VRK2-KD (bottom). Ub, ubiquitin. (C) CCT1 was also degraded in cells overexpressing
VRK2. VRK2 has no effect on degradation of CCT2 and CCT7. (D) VRK2 does not affect CCT4 mRNA stability. Cells were transfected with Flag-VRK2 or
Flag-VRK2-KD and then treated with actinomycin D (10 g/ml), a transcription inhibitor. (E) Decreased TRiC protein stability was dependent on VRK2
enzymatic activity through the proteasomal degradation pathway. Cells were harvested at the indicated times after cycloheximide (100 g/ml) treatment to
inhibit protein synthesis, and endogenous CCT4 was detected by Western blotting. The endogenous CCT4 protein turnover rate accelerated in cells overex-
pressing Flag-VRK2 but not in those overexpressing Flag-VRK2-KD. (F) The CCT4 protein turnover rate was quantified. The error bars represent the mean	
SEM (n
 3).
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and eventually results in the suppression of polyQ aggregation.
This provides more reliable evidence that VRK2 negatively regu-
lates TRiC.
Involvement of COP1 E3 ligase in VRK2-mediated TRiC
turnover. VRK2 increased CCT4 polyubiquitination of CCT4,
which induced CCT4 turnover (Fig. 2). We were interested in
determining which E3 ligase was activated by VRK2 and whether it
could function as a ubiquitin ligase for CCT4. Because increased
CCT4 ubiquitination was dependent on VRK2 enzymatic activity,
it raises the possibility that phosphorylation could affect ubiquiti-
nation. Phosphorylation-dependent ubiquitination is a well-
known phenomenon described for the cullin-based RING E3 li-
gase complex (34). To identify which E3 ligase was involved in
CCT4 protein ubiquitination, we screened RING E3 ligases using
siRNA and determined which one restored CCT4 protein levels in
VRK2-overexpressing cells. COP1 E3 ligase was previously re-
ported to interact with TRiC (35) and strongly bound to it (Fig.
6A). The observed VRK2-mediated downregulation of TRiC in
Fig. 2B was reversed in siRNA against COP1-transfected cells (Fig.
6B). COP1 functions as an E3 ligase by forming a supercomplex
that also includes heterodimeric substrate receptor DET1, adaptor
DDB1, scaffold Cul4A, and RBX1 to recruit the E2 enzyme (36).
To verify this observation, we first tested the functional interac-
tion between VRK2 and COP1 with an in vitro kinase assay. Al-
though RBX1 directly bound to VRK2 (Fig. 6C), we could not
detect the phosphorylated RBX1, nor could we detect COP1 or the
E2 enzyme (see Fig. S6 in the supplemental material). Next, we
analyzed the action of the COP1 E3 ligase supercomplex on CCT4
ubiquitination with an in vitro ubiquitination assay. The recom-
binant COP1 supercomplex derived from E. coli showed an in-
creased ability to ubiquitinate CCT4 in vitro, and COP1-mediated
polyubiquitination of CCT4 was markedly enhanced in the pres-
ence of VRK2 (Fig. 6D). The results suggest that VRK2 enables the
COP1 complex to efficiently attach ubiquitin on the CCT4 by
providing a close interaction between CCT4 and the COP1 com-
plex. As previously reported, the ubiquitin-proteasome system
(UPS) plays an important role in determining TRiC’s half-life (6
to 7 h) (29). The effect of targeted knockdown of VRK2 and COP1
on the CCT4 protein turnover rate was examined after treatment
with the translation inhibitor cycloheximide (CHX). The protein
stability of CCT4 was significantly enhanced in cells transfected
with siRNAs for VRK2 and COP1 (Fig. 6E). Thus, the results sug-
gest that increased CCT4 ubiquitination by VRK2 was mediated
by COP1 E3 ligase, and the interaction with RBX1 was especially
important.
DISCUSSION
Although HD is a monogenic neurodegenerative disorder known
to be caused by expansion of Htt’s polyQ tract, there is no thera-
peutic treatment. Mutant Htt causes dysfunction in numerous
signaling pathways and affects several molecular mechanisms, in-
cluding transcription, axonal transport, and mitochondrial and
FIG 3 VRK2-mediated degradation of TRiC increases polyQ-expanded Htt aggregation in mammalian cells. (A) HttQ103-GFP and DsRed1-C1-VRK2 (or
-VRK1) were coexpressed in HEK293T cells, and fluorescent images were analyzed. (B) We calculated the percentage of cells containing foci of HttQ103-GFP
aggregates in double-fluorescence-positive cells. The error bars represent the mean 	 SD (n 
 3). *, P  0.05. (C) Fluorescence microscopic images of
HttQ103-GFP expressed in HEK293 and neuroblastoma SH-SY5Y cells. GFP aggregates in both cell types were increased only by overexpression of wild-type
VRK2 and not by overexpression of VRK2-KD. (D, E) We calculated the percentage of HEK293 (D) and SH-SY5Y (E) cells containing foci of HttQ103-GFP
aggregates. The error bars represent the mean	 SEM (HEK293 cells, n
 4; SH-SY5Y cells, n
 3). *, P 0.05. (F) Filter-trap assay of HttQ103-GFP aggregates.
Cell lysates containing the indicated amount of protein were filtered on cellulose acetate membranes and immunoblotted with anti-GFP antibody to detect
HttQ103-GFP aggregates. (G) Flag-VRK2 with HttQ103-GFP or HttQ25-GFP was coexpressed in HEK293T cells and then analyzed by Western blotting to detect
polyQ aggregates. Bars, 10 m (A) and 80 m (C).
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synaptic functions (7). Although mutant Htt aggregation is
known to be involved in HD development, the pathogenic mech-
anism leading to cell damage and death remains controversial.
Because the formation of polyQ-containing aggregates is consid-
ered the hallmark of HD, it would be beneficial to prevent this
process. Therefore, popular therapeutic strategies, including the
inhibition of misfolded aggregation-prone proteins through mo-
lecular chaperone expression (17, 37–39) or clearance through the
autophagic pathway (40–42), have been proposed for HD and
other neurodegenerative disorders.
Our present results provide evidence for molecular chaperone-
mediated alleviation of protein aggregation through TRiC protein
FIG 4 Rescue of TRiC alleviates polyQ-expanded huntingtin aggregation. (A) HttQ103-GFP and Flag-VRK2 with or without HA-CCT4 were coexpressed in
HEK293T cells, and fluorescence microscopic images were analyzed. Bar, 20 m. (B) The percentage of cells with HttQ103-GFP aggregate foci was calculated.
The error bars represent the mean	 SEM (n
 4). *, P 0.05. (C) The amounts of HttQ103-GFP aggregates were investigated by Western blotting using an
anti-GFP antibody. The insoluble aggregates remained at the top of the gel, and soluble HttQ103-GFP entered the resolving gel. (D) Filter-trap assay for analysis
of the insoluble aggregates in cells transfected with the indicated vectors.
FIG 5 Knockdown of VRK2 decreases formation of polyQ-expanded huntingtin aggregates. (A) HttQ103-GFP with or without siRNA against VRK2 was coexpressed
in U2OS cells, and HttQ103 aggregates were investigated by immunoblotting. (B) Fluorescence microscopy of HttQ103-GFP expressed in HeLa cells treated with siVRK2
or siCont. VRK2 depletion decreased the number of cells containing HttQ103-GFP aggregates. Bar, 20m. (C) The percentage of aggregate-positive cells from panel B
was calculated. The error bars represent the mean	 SD (n
 3). **, P 0.01 versus siCont-treated cells at 2 and 3 days; n.s, not significant.
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turnover. In summary, we have shown that VRK2 specifically
binds TRiC, which affects its degradation (Fig. 1 and 2). Physio-
logically, impairment of TRiC by wild-type VRK2 hyperactivation
increases polyQ aggregation, whereas VRK2 KD has no effect (Fig.
3). VRK2-mediated downregulation of TRiC required COP1 E3
ligase activity (Fig. 6). A previous study demonstrated that over-
expression of TRiC subunit CCT1 (or CCT4) reduced polyQ foci
by directing newly made polyQ proteins to nonpathogenic con-
formations via an interaction between CCT1 (or CCT4) and
polyQ proteins (17). Our system clearly showed that the reduction
of polyQ aggregation occurred in the presence of HA-CCT4 over-
expression, despite VRK2 overexpression (Fig. 4).
Aggregation-based diseases disproportionately affect postmi-
totic cells, such as neurons, presumably because toxic protein ag-
gregates accumulate easily in undividing cells (6). In our study,
neuroblastoma SH-SY5Y cell viability was reduced by pathogenic
HttQ103-GFP expression, and VRK2 overexpression increased
HttQ103-GFP aggregate formation in SH-SY5Y cells, suggesting
that the level of active VRK2 in neuronal cells may be important
for the onset and progression of polyQ diseases. Moreover, ge-
nome-wide association studies have revealed that VRK2 has
emerged as one of the risk factors against neurological disorders,
including schizophrenia (43, 44) and epilepsy (45, 46). VRK2 ex-
pression, however, is known to be much higher in actively prolif-
erating cells and is maintained at a low level in the brain (47).
Analysis of VRK2 mRNA levels revealed that the relative amount
in neural SK-N-BE(2)C cells was 600-fold lower than that in non-
neural HEK293T cells (unpublished data). These results raise the
possibility that neuronal cells maintain very low levels of VRK2
because it makes cells prone to polyQ aggregation. To prove this,
it would be very important to determine whether VRK2 levels are
increased in HD brain tissue. In support of this concept, a pro-
gressive decrease of molecular chaperones was observed in a
mouse model of HD, and this affected disease symptoms (38).
According to transcriptome analysis, expression of Cul4A, a com-
ponent of the COP1 E3 ligase supercomplex, is upregulated in a
mouse model of HD (48), which supports the possibility of im-
paired TRiC function in HD pathogenesis.
Our findings demonstrate that the enzymatic activity of wild-
type VRK2 protein correlates with pathogenic polyQ aggregation
in cells and support the hypothesis that VRK2 mediates activity-
dependent functional impairment of TRiC. TRiC is known to af-
fect polyQ aggregation (13); growing evidence demonstrates that
it is essential for trapping aggregation-prone structures to prevent
expanded polyQ proteins from misfolding and aggregating. How-
ever, the upstream regulator of TRiC and the exact function of
VRK2 had been unknown. Thus, our results are important in that
we identified a regulator of TRiC, discovered a new function of
VRK2 in the aggregation process of polyQ-containing proteins,
and demonstrated that COP1 can be recruited to TRiC by inter-
acting with VRK2 and another upstream regulator to destabilize
TRiC and facilitate polyQ protein aggregation (Fig. 7). Taken to-
gether, our results identify VRK2 as a modulator that suppresses
the TRiC-assisted folding pathway of polyQ proteins. Further re-
search is necessary to identify the target substrate of VRK2 in TRiC
downregulation. Our study provides clues for the genesis of polyQ
FIG 6 COP1 E3 ligase is involved in VRK2-mediated TRiC protein turnover. (A) Immunoprecipitation assay using HEK293T cells cotransfected with Flag-
COP1 and HA-CCT4 vectors. Encoded HA-CCT4 was coimmunoprecipitated with an anti-Flag antibody. (B) VRK2-mediated downregulation of TRiC
disappeared in cells transfected with siCOP1. (C) GST pulldown assay using in vitro-purified SUMO-VRK2 and GST-RBX1 recombinant proteins. (D) VRK2
enhanced CCT4 ubiquitination by the COP1 E3 ligase supercomplex in vitro. Purified HIS-CCT4 was incubated with components of the ubiquitin system in the
presence or absence of the COP1 E3 ligase supercomplex with or without VRK2. Polyubiquitinated CCT4 was immunoblotted with an anti-Flag antibody to
detect Flag-ubiquitin. (E) Knockdown of both VRK2 and COP1 enhanced CCT4 protein stability. Cells were harvested at the indicated times after cycloheximide
(40 g/ml) treatment, and then endogenous CCT4 was detected by Western blotting.
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diseases and for developing VRK2-targeted therapeutic inhibitors
of neurodegenerative disorders caused by polyQ-containing pro-
tein aggregates that play a role in many neurodegenerative dis-
eases.
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